Benefits
Iron levels in pregnant women with low iron stores
In a randomized trial of 111 pregnant women with iron-deficiency anemia, 27 mg/day of iron as emulsified ferric pyrophosphate raised hemoglobin by 2.63 g/dL in 4 weeks, matching 100 mg/day as ferrous ascorbate (2.62 g/dL). It was open-label, short and paid for by the product's maker, and the test tablet also held vitamin C and folic acid.
Fewer stomach complaints than ferrous iron salts
In the 111-woman pregnancy trial, nausea, dark stools and acidity were reported only on ferrous ascorbate (11.1% had side effects), not on ferric pyrophosphate. In a 50-woman double-blind trial, 24% had side effects on ferrous gluconate against none of note on 30 mg micronized ferric pyrophosphate taken with alpha-lactalbumin. The first trial gave far less iron in the ferric pyrophosphate arm.
Raises iron stores when added to staple foods
In double-blind trials in iron-depleted schoolchildren, rice fortified with micronized ferric pyrophosphate (about 19 to 20 mg iron a day for 7 to 8 months) raised iron stores and cut iron deficiency compared with plain rice. Salt fortified with it raised iron stores in two trials, but hemoglobin rose in only one of them.
Absorption depends on particle size and the food it is in
Standard ferric pyrophosphate (particles about 8.5 micrometres) was absorbed about a third as well as ferrous sulfate in women. A micronized, dispersible form (about 0.3 micrometres, with emulsifiers) was absorbed about as well as ferrous sulfate from a cereal and a yogurt drink in two 10-woman isotope studies. In a 26-woman study of another micronized form, it reached 62% of ferrous sulfate in a cereal but 15 to 24% in rice meals.
Iron and ferritin levels in adults with iron deficiency
In an observational study of 119 adults with iron deficiency taking micronized, emulsified ferric pyrophosphate for 3 months, iron rose in 39 of 63 women with repeat tests and ferritin in 38 of 66 patients, and 83% rated the product good or very good. A 60-person single-arm study also reported rising hemoglobin and ferritin. Neither study had a control group.
Little effect on the taste or color of fortified foods
This is the main reason food makers use it. Rice fortified with micronized ferric pyrophosphate could not be told apart from natural rice in sensory tests, cooked or uncooked, and dual-fortified salt kept the same color as iodized salt after 6 months of storage. The FDA lists ferric pyrophosphate as generally recognized as safe for use as a nutrient.
Mechanism of action
Insoluble iron that must dissolve before it is absorbed
Ferric pyrophosphate does not dissolve in water, so little of it is freed in the gut, which is why absorption from the standard powder is low. Grinding it into much smaller particles and keeping them suspended with emulsifiers or a coating gives more surface to dissolve, which is the idea behind micronized and encapsulated forms.
Absorption is not stepped up much when iron is low
The body absorbs more iron from soluble salts such as ferrous sulfate when its iron stores are low. In isotope studies in 49 young women, ferritin strongly predicted absorption from ferrous sulfate but not from ferric pyrophosphate, so ferrous sulfate gains a larger edge in people with low iron.
Vitamin C helps, but less than with ferrous sulfate
Adding vitamin C to a fortified cereal meal raised absorption from ferric pyrophosphate about 2.6-fold, against about 3.7-fold for ferrous sulfate. In a second study, vitamin C took micronized ferric pyrophosphate from 2.0% to 5.8% absorbed and ferrous sulfate from 3.2% to 14.8%.
Clinical trials
Two stable-isotope absorption studies comparing micronized, dispersible ferric pyrophosphate (SunActive Fe, average particle size 0.3 micrometres, with emulsifiers) with ferrous sulfate, each at 5 mg iron per test meal (Fidler et al. 2004, Br J Nutr).
20 adult women (10 per study), fed an infant cereal or a yogurt drink.
Absorption did not differ significantly: 3.4% vs 4.1% from the cereal (P = 0.24) and 3.9% vs 4.2% from the yogurt drink (P = 0.72). These were single test meals measuring absorption, not changes in iron status.
Three stable-isotope studies of ferric pyrophosphate in an iron-fortified infant cereal (5 mg iron per meal), with ferrous sulfate as the reference (Fidler et al. 2004, Int J Vitam Nutr Res).
Adult women, 9 to 10 per study.
Absorption from ferric pyrophosphate (particles about 8.5 micrometres) was 0.9% against 2.6% for ferrous sulfate without vitamin C (36% relative bioavailability) and 2.3% against 9.7% with vitamin C (23%). Smaller particles of 6.7 micrometres did not absorb significantly better than 12.5 micrometres (52% vs 42% relative bioavailability).
Stable-isotope test meals in women selected for low or high iron status, plus a re-analysis of earlier salt fortification trials in children (Zimmermann et al. 2011, Br J Nutr).
49 young women; data from 258 children in previous efficacy trials.
Plasma ferritin strongly predicted absorption from ferrous sulfate (P < 0.0001) but not from ferric pyrophosphate. In the child trials, low starting body iron predicted a bigger gain with both compounds, but significantly more so with ferrous sulfate (P < 0.01).
Double-blind, randomized, 7-month school lunch trial in Bangalore, India: a rice meal fortified with 20 mg iron as micronized ground ferric pyrophosphate vs an identical unfortified meal; all children dewormed (Moretti et al. 2006, Am J Clin Nutr).
184 iron-depleted children aged 6 to 13; 78% iron deficient and 29% with iron-deficiency anemia at baseline.
Body iron stores rose more in the iron group (P < 0.05). Among dewormed children, iron deficiency fell from 78% to 25% with iron and from 79% to 49% in controls. Iron-deficiency anemia fell from 30% to 15% in the iron group, which was not statistically significant. The fortified rice was indistinguishable from natural rice in sensory tests.
Double-blind, randomized, placebo-controlled 8-month feeding trial in India: a school midday meal with rice providing 19 mg iron as micronized ferric pyrophosphate in extruded kernels vs unfortified rice (Radhika et al. 2011, Am J Clin Nutr).
140 schoolchildren aged 5 to 11.
Ferritin rose by 8.2 mcg/L with fortified rice (P < 0.001) and iron deficiency fell from 33% to 14%, against 31% to 37% in controls. Hemoglobin rose similarly in both groups (0.99 vs 1.15 g/dL), and anemia prevalence did not differ between groups.
Randomized, double-blind 10-month trial of salt fortified with iodine and 2 mg iron per gram as micronized ferric pyrophosphate vs iodized salt, in rural northern Morocco (Zimmermann et al. 2004, Am J Clin Nutr).
158 iodine-deficient children aged 6 to 15 with a high rate of anemia.
The fortified salt supplied about 18 mg iron a day, with absorption estimated at about 2%. Mean hemoglobin rose 16 g/L (P < 0.01), iron stores rose, and iron-deficiency anemia fell from 30% to 5% (P < 0.001). Salt color and iodine content did not change over 6 months of storage.
Double-blind 6-month trial of salt fortified with iodine and 3 mg iron per gram as micronized ground ferric pyrophosphate vs iodized salt; children dewormed at baseline (Wegmuller et al. 2006, J Nutr).
123 iron-deficient children aged 5 to 15 in rural Cote d'Ivoire, 55% of whom had malaria.
Ferritin, transferrin receptor and body iron stores improved in the fortified-salt group but not with iodized salt (body iron 4.6 to 5.9 mg/kg). Hemoglobin and anemia prevalence did not change in either group; the authors suggest malaria and other nutrient deficiencies limited iron use.
Randomized, open-label, multicenter 4-week trial of SunActive Fe tablets (27 mg iron, also containing vitamin C, vitamin B12, folic acid and glycine) vs ferrous ascorbate (100 mg iron with folic acid); material and testing costs were paid by Generex Pharmassist, whose staff were co-authors (Patki et al. 2025, Sci Rep).
111 second-trimester pregnant women in India aged 20 to 35 with hemoglobin 9 to 10.5 g/dL and ferritin below 15 mcg/L; 108 completed.
Hemoglobin rose by a similar amount (2.63 vs 2.62 g/dL) and ferritin by a similar share (61.09% vs 61.92%). No adverse effects were reported on ferric pyrophosphate, against 11.1% on ferrous ascorbate (nausea, dark stools, acidity). The design was open-label and short, and the doses were not matched.
Double-blind, randomized 30-day trial at one center in Rome: one daily tablet of 30 mg micronized dispersible ferric pyrophosphate plus 300 mg alpha-lactalbumin (Emogut Forte) vs one tablet of 80 mg ferrous gluconate; no specific funding (Laganà et al. 2018, Eur Rev Med Pharmacol Sci).
50 second-trimester pregnant women with iron-deficiency anemia (hemoglobin below 10.5 g/dL); all 50 completed.
Hemoglobin, ferritin and serum iron rose in both groups. At 30 days hemoglobin had risen 16.35% vs 10.68%, a significantly larger rise with ferric pyrophosphate (P < 0.0001). Side effects occurred in 24% on ferrous gluconate, with no significant side effects on ferric pyrophosphate. The added alpha-lactalbumin means the result cannot be credited to the iron form alone.